GlobeNewsWire
11 Nov 2026, 13:37 UTC · 3h ago
Impact · against what's priced in
NeOnc (NTHI) shares are likely to see a positive catalyst as the company formalizes a path toward accelerated FDA approval for NEO100. The move toward a 505(b)(2) NDA pathway could significantly shorten the time to market compared to standard Phase 3 requirements.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
NeOnc secured an FDA Type B End-of-Phase meeting for early January 2027 to discuss accelerated approval for NEO100.
Newpress release dated Nov 11
More positive than 93% of claims this week
The company intends to seek feedback on whether a 505(b)(2) NDA pathway is supported by current evidence for IDH-mutant grade 4 astrocytoma.
New
Continue reading
5 related stories
The scheduling of a Type B End-of-Phase meeting to discuss an accelerated 505(b)(2) NDA pathway for IDH-mutant grade 4 astrocytoma provides a concrete regulatory timeline and a potentially faster route to commercialization.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
NeOnc is preparing for a randomized Phase 3 study for its NEO100 treatment.
Newpress release dated Nov 11
So whatThe transition to Phase 3 typically triggers a significant increase in R&D spend for the coming fiscal year.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
Secured an FDA meeting to discuss a potential accelerated approval pathway for its brain cancer treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
17h ago
+5.0%
Price agrees with the score
$4.59 vs $4.37 close before publication (Nov 10) · not market-adjusted
NTHI chart →
